home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Souped Up Immune Cells With A Deadly Cargo

 
  March, 2 2002 2:19
your information resource in human molecular genetics
 
     
Scientists have coopted immune cells as agents for delivering anticancer gene therapy. Although the system is far from testing in humans, the approach could complement more traditional cancer treatments such as chemotherapy.

Although cancer gene therapy is a potentially powerful adjunct to conventional cancer therapies, its use in clinical settings has been severely limited due to the undesirable foreign gene expression in tissues other than the tumor. To create a gene therapy delivery system more specific to tumors, researchers led by Richard Vile have employed T cells, a class of immune cells that preferentially targets tumors as a means of delivering a “suicide” gene to cancer cells (Nature Biotechnology, Vol. 20, No. 3, March 1, 2002).

The researchers first set about tailoring T cells to be specific to tumors by incorporating into their DNA a gene expressing a receptor that binds to a tumor-specific cell-surface protein called carcinoembryonic antigen (CEA). To turn the T cells into potent cancer-killing agents, they were engineered to produce a virus carrying a toxic gene (thymidine kinase). This gene, which originates from herpes simplex virus and is not normally present in cells, encodes a protein that converts a relatively harmless prodrug, ganciclovir, into a cancer killing poison. To add an even greater level of control, they also placed the thymidine kinase gene under the control of a regulatory element (the CEA promoter) that is active only in tumor cells.

The authors demonstrate the potency of their approach both in tissue culture as well as in mice with lung and liver metastases. Further studies—for example, to make sure that enough virus is produced by the T cells during their lifetime in the body—will be required before this system can be tested in humans.

Contact: (author)

Richard Vile
Molecular Medicine Program
Guggenheim 18, Mayo Clinic
200 First Street SW
Rochester, MN
Email: richard.vile@mayo.edu

(News and Views)

E. Antonio Chiocca
Molecular Neuro-oncology and Neurosurgery
Massachusetts General Hospital
Harvard Medical School
Boston, MA
02114
Email: chiocca@helix.mgh.harvard.edu

(C) Nature Biotechnology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.